Hansoh Pharmaceutical Group Company Limited (HNSPF)
| Market Cap | 25.17B +69.7% |
| Revenue (ttm) | 1.84B +9.0% |
| Net Income | 667.42M +1.4% |
| EPS | 0.11 +5.9% |
| Shares Out | n/a |
| PE Ratio | 37.71 |
| Forward PE | 33.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109 |
| Average Volume | 1,511 |
| Open | 5.16 |
| Previous Close | 4.58 |
| Day's Range | 5.16 - 5.16 |
| 52-Week Range | 2.70 - 5.20 |
| Beta | 0.60 |
| RSI | 63.76 |
| Earnings Date | Mar 29, 2026 |
About HNSPF
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]
Financial Performance
In 2024, HNSPF's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.
Financial numbers in CNY Financial StatementsNews
Innovent's License Deal Fails To Excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $ 11.4 billion, pocketing a big downpayment, so why did its stock price fall? Key Takeaways: Innovent and it...